Relmada Therapeutics (RLMD)

• Market cap: $23.2M
• 1 day: -0.85%
• 5 days: -17.08%
• 1 month: 79.54%
• 3 months: 157.62%
• 6 months: 90.79%
• Year to date: 55.57%
• 1 year: -76.74%
• 5 years: -98.55%
• 10 years: -93.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Employees: 17

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

7.22% less ownership

Funds ownership: 27.84% [Q4 2024] → 20.61% (-7.22%) [Q1 2025]

8% less funds holding

Funds holding: 48 [Q4 2024] → 44 (-4) [Q1 2025]

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

62% less capital invested

Capital invested by funds: $4.36M [Q4 2024] → $1.68M (-$2.68M) [Q1 2025]

71% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 14